Genetic errors identified in 12 major cancer types
The research, published Oct. 17 in Nature, shows that some of the same genes commonly mutated in certain cancers also occur in seemingly unrelated tumors. …
The research, published Oct. 17 in Nature, shows that some of the same genes commonly mutated in certain cancers also occur in seemingly unrelated tumors. …
Their study, published today in the Proceedings of the National Academy of Sciences (PNAS) suggests the compound, already shown to be safe for humans, may protect normal tissues during radiation therapy for cancer treatment and prevent or mitigate sickness caused by radiation exposure. The compound, known as DIM (3,3′-diindolylmethane), previously has been found to have cancer preventive properties. "DIM has been studied as a cancer prevention agent for years, but this is the first indication that DIM can also act as a radiation protector," says the study’s corresponding author, Eliot Rosen, MD, PhD, of Georgetown Lombardi Comprehensive Cancer Center. For the study, the researchers irradiated rats with lethal doses of gamma ray radiation…
The database was developed by identical twin brothers, Obi Griffith, PhD, and Malachi Griffith, PhD, whose interest in pairing drugs with genes is as much personal as it is scientific. Their mother died of breast cancer 17 years ago, just weeks before their high school graduation. "We wanted to create a comprehensive database that is user-friendly, something along the lines of a Google search engine for disease genes," explained Malachi Griffith, a research instructor in genetics. "As we move toward personalized medicine, there’s a lot of interest in knowing whether drugs can target mutated genes in particular patients or in certain diseases, like breast or lung cancer. …
The research, published in the October issue of the journal Clinical Cancer Research, provides important evidence that PARP inhibitor drugs and chemotherapy can both be effective in the same patients, helping women live longer than they would if treated with chemotherapy alone. …
"The genetic risk factor we identified is associated with one of the largest risks ever reported for cancer," says study author Douglas Bell of the National Institute of Environmental Health Sciences at the National Institutes of Health. "We think it might prove useful for identifying individuals at the highest risk for cancer or who might benefit from preventive or therapeutic treatments." About half of human cancers are associated with mutations in the p53 gene, which regulates vital cell functions as well as tumor formation in many tissues. Because p53 must activate a wide range of genes to influence cancer-related signaling pathways, Bell and Gareth Bond of the University of Oxford and the Ludwig Institute for Cancer Research speculated that cancer risk could be associated with genetic variation in p53-binding sites. …
As explicated today in the journal Nature, methylation in fact enforces gene silencing, and it is levels of a newly identified form of RNA produced by individual genes that determines whether they are turned off by the addition of a methyl (CH3) group by the enzyme DNA methylase 1 (DNMT1). The study, led by HSCI Principal Faculty member Daniel Tenen, MD, found that during transcription of DNA to RNA, a gene produces a small amount of what the investigators named "extracoding RNA," which stays in the nucleus and binds to DNMT1, blocking its ability to methylate, or silence the gene. The discovery of RNA’s new function has therapeutic potential as an on-off switch for gene expression. "We have demonstrated, at least for one gene in detail, and probably thousands more, that extracoding RNA serves to protect the gene from methylation," said Tenen, who heads laboratories at Beth Israel Deaconess Medical Center and the Cancer Science Institute of Singapore, where he is director, at the National University of Singapore. …
As explicated today in the journal Nature, methylation in fact enforces gene silencing, and it is levels of a newly identified form of RNA produced by individual genes that determines whether they are turned off by the addition of a methyl (CH3) group by the enzyme DNA methylase 1 (DNMT1). The study, led by HSCI Principal Faculty member Daniel Tenen, MD, found that during transcription of DNA to RNA, a gene produces a small amount of what the investigators named "extracoding RNA," which stays in the nucleus and binds to DNMT1, blocking its ability to methylate, or silence the gene. The discovery of RNA’s new function has therapeutic potential as an on-off switch for gene expression…
The Cell Division & Cancer Group, led by Spanish National Cancer Research Centre (CNIO) researcher Marcos Malumbres, has managed to decode a new mechanism that regulates cell division, in which the key molecule involved, Greatwall − also known as Mastl− could be a new therapeutic target for oncology treatments. The study is published today in the scientific journal Proceedings of the National Academy of Sciences (PNAS). GREATWALL: A KEY PLAYER OF THE CELL DIVISION PUZZLE The control of cell division or mitosis depends on many proteins, amongst them, Aurora and Polo. Currently, many pharmaceutical companies have shown interest in these molecules, for which inhibitors have already been developed, some of which are currently undergoing clinical trials in oncology…
These findings, being published in the Oct. 4, 2013, online edition of PLOS ONE, also show that the use of a biotherapy consisting of a lysosomal protein, known as saposin C (SapC), and a phospholipid, known as dioleoylphosphatidylserine (DOPS), can be combined into tiny cavities, or nanovesicles, to target and kill pancreatic cancer cells…
The study was led by Francisco X. Real, head of the Epithelial Carcinogenesis Group at CNIO, together with Nuria Malats, the head of the Genetic & Molecular Epidemiology Group at CNIO, as well as other European groups, especially Yves Allory, a pathologist at the Mondor Hospital (Créteil, Paris, France), who is on a sabbatical year with Real and Malats’s groups at CNIO, and Ellen Zwarthoff’s group at the Erasmus Medical Centre in Rotterdam. The results are published in the online version of the journal European Urology. …